Advances in the Application of Fondaparinux in Acute Coronary Syndrome

Han, Xue; Jin, Lina

doi:10.4236/crcm.2020.97028

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No other plasma proteins or cellular components, such as platelets or platelet factor 4, can be bound to or interacted with by fondaparinux. Unlike enoxaparin and UFH, Fondaparinux can cause a syndrome such as heparin-induced thrombocytopenia (Szummer et al, 2015;Han & Jin, 2020;Khan et al, 2022).…”

Section: Anticoagulant Profile Of Hospitalised Patientsmentioning

confidence: 99%

Use of anticoagulant drugs for hospitalised patients: A multicentre study

Annisa,

Kartikawati,

Ningrum

2024

Pharm Educ

View full text Add to dashboard Cite

Background: Anticoagulants are indicated for several types of diseases with progression related to coagulation. Patients administered this drug need to be evaluated by the pharmacist regarding its effectiveness and possible side effects. Objective: This research aimed to analyse the profile use of anticoagulants among patients at Yogyakarta Hospital. Method: This research was a multicentre study conducted retrospectively using the medical records of inpatients who received anticoagulants. Result: Among a total of 486 respondents, the majority were male (63.58%), and the adult age category (18-59 years) was 55.76%. Most anticoagulants were used in cases of cardiovascular disease, diagnosed with NSTEMI as much as 20.21%. The most used anticoagulant drug was heparin (48.9%), followed by fondaparinux (34.3%) and enoxaparin (16.8%). The most duration of anticoagulant use was one to four days (73.02%) with the dose range being 200-1000 units/day. Conclusion: Heparin was the anticoagulant widely used in patients with NSTEMI. Although the elderly were the group most at risk of ADR due to anticoagulants, most of these drugs were precisely taken by adults, who also required serious attention. Further research is needed to provide a more comprehensive approach to anticoagulant therapy.

show abstract

Section: Anticoagulant Profile Of Hospitalised Patientsmentioning

confidence: 99%

Use of anticoagulant drugs for hospitalised patients: A multicentre study

Annisa,

Kartikawati,

Ningrum

2024

Pharm Educ

View full text Add to dashboard Cite

show abstract

“…10 On the other hand different registry-based data provided evidence in favor of fondaparinux compared to enoxaparin in terms of cost effectivity and efficacy. [11][12][13][14][15][16][17][18][19][20][21][22] Though data from different settings are increasingly available in the literature regarding the comparative benefit of fondaparinux over enoxaparin in cases of NSTE-ACS, this issue is rarely addressed in Bangladesh. In this background, this study is designed to compare fondaparinux to enoxaparin in in-hospital prognosis and short-term outcome of NSTE-ACS in a group of Bangladeshi population.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Fondaparinux Versus Enoxaparin in The Management of Unstable Angina and NSTEMI

Rahman,

Ali,

Ahmed

et al. 2024

Bangladesh Heart J

View full text Add to dashboard Cite

Background: Unstable angina (UA) and Non-ST elevation myocardial infarction (NSTEMI) impose significant health and economic burden on Bangladesh. Anticoagulants are recommended as standard therapy by various clinical practice guidelines. Recent studies have shown fondaparinux's superiority over enoxaparin in patients with UA & NSTEMI, especially in bleeding reduction. The description of this finding has not yet been documented in any study from Bangladesh. This study aimed to evaluate the efficacy and safety of fondaparinux compared with enoxaparin in the management of UA & NSTEMI. Methods: This prospective observational study included 177 patients (fondaparinux=87, enoxaparin=90) with UA and NSTEMI admitted to the Department of Cardiology of Abdul Malek Ukil Medical College Hospital, Noakhali, Bangladesh. The primary outcome was to determine whether fondaparinux was non-inferior to enoxaparin in preventing the composite of death, new myocardial infarction, and refractory ischemia, readmission in the hospital for heart failure within six months after anticoagulant therapy. The primary safety outcome was to evaluate the rates of major bleeds in the two groups. Results: The minor (6.9% versus 20%, p=0.002) and major (0% versus 3.3%, p=0.002) bleeding events were less frequently observed with Fondaparinux than enoxaparin. Myocardial ischemia (3.4% vs. 14.4%, p=0.011) and recurrent ischemia (11.5% vs. 24.4%, p=0.025) were less frequent in Fondaparinux than in the enoxaparin group. Fondaparinux was associated with a reduced number of deaths in 3 months (6.2% vs. 12.5%) and 6 months (5.1% vs. 13.3%) without any statistical significance (p>0.05). In the fondaparinux group, 20.7% of patients experienced a composite event within 6 months, compared with 40% of patients in the enoxaparin group (OR:0.659, 95% CI 0.500-0.867, p=0.005). Conclusion: Similarly, to recently published data in international literature, fondaparinux proved superior to enoxaparin for the Bangladeshi population, with a significant reduction of combined events and bleeding in patients with UA & NSTEMI. Bangladesh Heart Journal 2024; 39(1): 31-37

show abstract

Advances in the Application of Fondaparinux in Acute Coronary Syndrome

Cited by 2 publications

References 16 publications

Use of anticoagulant drugs for hospitalised patients: A multicentre study

Use of anticoagulant drugs for hospitalised patients: A multicentre study

Efficacy and Safety of Fondaparinux Versus Enoxaparin in The Management of Unstable Angina and NSTEMI

Contact Info

Product

Resources

About